NRx signs licensing deal for experimental bipolar depression treatment valued at up to $345M
The commercialization rights to the potential treatment were acquired by Lotus Pharmaceuticals of Taiwan and Alvogen in North Jersey.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news